BACKGROUND Recently,Olympus Corporation released new scopes(XZ1200/EZ1500).However,there have been few reports on this topic,although improvement in adenoma detection rate(ADR)by texture and color enhancement imaging(...BACKGROUND Recently,Olympus Corporation released new scopes(XZ1200/EZ1500).However,there have been few reports on this topic,although improvement in adenoma detection rate(ADR)by texture and color enhancement imaging(TXI)or computer-aided detection system(CAD)has been reported.AIM To investigate the effects of the scope on the detection of adenomas and sessile serrated lesions(SSLs).METHODS The subjects were patients who underwent pancolonic chromoendoscopy using the EVIS X1 video system center between May 2023 and October 2024.The patients were divided into the new(CF-XZ1200/CF-EZ1500)and 290 series(CF-HQ290Z/PCF-H290Z)groups.Propensity score matching was performed for age,sex,examination purpose,endoscopist,preparation,TXI use,and CAD use.The effects of the scope were analyzed in terms of the ADR,SSL detection rate(SDR),and mean number of adenomas per colonoscopy(APC).RESULTS Of the 7014 patients enrolled,2138 pairs were extracted by propensity score matching(mean age 55.4 years,45.5%male).The new scopes group had a significantly higher ADR than the 290 series group[51.5%vs 45.5%,odds ratio(OR)=1.27,95%CI:1.13-1.43,P<0.001].Similarly,the new scopes group had significantly higher SDR(7.8%vs 5.7%,OR=1.41,95%CI:1.11-1.80,P=0.005)and APC(0.90 vs 0.76,OR=1.11,95%CI:1.05-1.17,P<0.001)than the 290 series group.CONCLUSION In conclusion,the new scope(CF-XZ1200/CF-EZ1500)enhanced the detection of adenomas and SSLs compared to the old ones(290 series).展开更多
BACKGROUND Transcatheter arterial chemoembolization(TACE)is the main treatment for patients with primary hepatocellular carcinoma(PHC)who miss the opportunity to undergo surgery.Conventional TACE(c-TACE)uses iodized o...BACKGROUND Transcatheter arterial chemoembolization(TACE)is the main treatment for patients with primary hepatocellular carcinoma(PHC)who miss the opportunity to undergo surgery.Conventional TACE(c-TACE)uses iodized oil as an embolic agent,which is easily washed by blood and affects its efficacy.Drug-eluting bead TACE(DEB-TACE)can sustainably release chemotherapeutic drugs and has a long embolization time.However,the clinical characteristics of patients before the two types of interventional therapies may differ,possibly affecting the conclusion.Only a few studies have compared these two interventions using propensity-score matching(PSM).AIM To analyze the clinical effects of DEB-TACE and c-TACE on patients with PHC based on PSM.METHODS Patients with PHC admitted to Dangyang People’s Hospital(March 2020 to March 2024)were retrospectively enrolled and categorized into groups A(DEB-TACE,n=125)and B(c-TACE,n=106).Sex,age,Child-Pugh grade,tumor-node-meta-stasis stage,and Eastern Cooperative Oncology Group score were selected for 1:1 PSM.Eighty-six patients each were included post-matching.Clinical efficacy,liver function indices(aspartate aminotransferase,alanine aminotransferase,total bilirubin,and albumin),tumor serum markers,and adverse reactions were compared between the groups.RESULTS The objective response and disease control rates were significantly higher in group A(80.23%and 97.67%,respectively)than in group B(60.47%and 87.21%,respectively)(P<0.05).Post-treatment levels of aspartate aminotransferase,alanine aminotransferase,and total bilirubin were lower in group A than in group B(P<0.05),whereas post-treatment levels of albumin in group A were comparable to those in group B(P>0.05).Post-treatment levels of tumor serum markers were significantly lower in group A than in group B(P<0.05).Patients in groups A and B had mild-to-moderate fever and vomiting symptoms,which improved with conservative treatment.The total incidence of adverse reactions was significantly higher in group B(22.09%)than in group A(6.97%)(P<0.05).CONCLUSION DEB-TACE has obvious therapeutic effects on patients with PHC.It can improve liver function indices and tumor markers of patients without increasing the rate of liver toxicity or adverse reactions.展开更多
Objective:The number of immediate breast reconstruction(IBR)procedures has been increasing in China.This study aimed to investigate the oncological safety of IBR,and to compare the survival and surgical outcomes betwe...Objective:The number of immediate breast reconstruction(IBR)procedures has been increasing in China.This study aimed to investigate the oncological safety of IBR,and to compare the survival and surgical outcomes between implant-based and autologous reconstruction.Methods:Data from patients diagnosed with invasive breast cancer who underwent immediate total breast reconstruction between 2001 and 2016 were retrospectively reviewed.Long-term breast cancer-specific survival(BCSS),disease-free survival(DFS),and locoregional recurrence-free survival(LRFS)were evaluated.Patient satisfaction with the breast was compared between the implantbased and autologous groups.BCSS,DFS,and LRFS were compared between groups after propensity score matching(PSM).Results:A total of 784 IBR procedures were identified,of which 584 were performed on patients with invasive breast cancer(implantbased,n=288;autologous,n=296).With a median follow-up of 71.3 months,the 10-year estimates of BCSS,DFS,and LRFS were 88.9%[95%confidence interval(CI)(85.1%–93.0%)],79.6%[95%CI(74.7%–84.8%)],and 94.0%[95%CI(90.3%–97.8%)],respectively.A total of 124 patients completed the Breast-Q questionnaire,and no statistically significant differences were noted between groups(P=0.823).After PSM with 27 variables,no statistically significant differences in BCSS,DFS,and LRFS were found between the implant-based(n=177)and autologous(n=177)groups.Further stratification according to staging,histological grade,lymph node status,and lymph-venous invasion status revealed no significant survival differences between groups.Conclusions:Both immediate implant-based and autologous reconstruction were reasonable choices with similar long-term oncological outcomes and patient-reported satisfaction among patients with invasive breast cancer in China.展开更多
基金Ethics Committee of the Certified Institutional Review Board of the Yoyogi Mental Clinic(No.RKK227).
文摘BACKGROUND Recently,Olympus Corporation released new scopes(XZ1200/EZ1500).However,there have been few reports on this topic,although improvement in adenoma detection rate(ADR)by texture and color enhancement imaging(TXI)or computer-aided detection system(CAD)has been reported.AIM To investigate the effects of the scope on the detection of adenomas and sessile serrated lesions(SSLs).METHODS The subjects were patients who underwent pancolonic chromoendoscopy using the EVIS X1 video system center between May 2023 and October 2024.The patients were divided into the new(CF-XZ1200/CF-EZ1500)and 290 series(CF-HQ290Z/PCF-H290Z)groups.Propensity score matching was performed for age,sex,examination purpose,endoscopist,preparation,TXI use,and CAD use.The effects of the scope were analyzed in terms of the ADR,SSL detection rate(SDR),and mean number of adenomas per colonoscopy(APC).RESULTS Of the 7014 patients enrolled,2138 pairs were extracted by propensity score matching(mean age 55.4 years,45.5%male).The new scopes group had a significantly higher ADR than the 290 series group[51.5%vs 45.5%,odds ratio(OR)=1.27,95%CI:1.13-1.43,P<0.001].Similarly,the new scopes group had significantly higher SDR(7.8%vs 5.7%,OR=1.41,95%CI:1.11-1.80,P=0.005)and APC(0.90 vs 0.76,OR=1.11,95%CI:1.05-1.17,P<0.001)than the 290 series group.CONCLUSION In conclusion,the new scope(CF-XZ1200/CF-EZ1500)enhanced the detection of adenomas and SSLs compared to the old ones(290 series).
文摘BACKGROUND Transcatheter arterial chemoembolization(TACE)is the main treatment for patients with primary hepatocellular carcinoma(PHC)who miss the opportunity to undergo surgery.Conventional TACE(c-TACE)uses iodized oil as an embolic agent,which is easily washed by blood and affects its efficacy.Drug-eluting bead TACE(DEB-TACE)can sustainably release chemotherapeutic drugs and has a long embolization time.However,the clinical characteristics of patients before the two types of interventional therapies may differ,possibly affecting the conclusion.Only a few studies have compared these two interventions using propensity-score matching(PSM).AIM To analyze the clinical effects of DEB-TACE and c-TACE on patients with PHC based on PSM.METHODS Patients with PHC admitted to Dangyang People’s Hospital(March 2020 to March 2024)were retrospectively enrolled and categorized into groups A(DEB-TACE,n=125)and B(c-TACE,n=106).Sex,age,Child-Pugh grade,tumor-node-meta-stasis stage,and Eastern Cooperative Oncology Group score were selected for 1:1 PSM.Eighty-six patients each were included post-matching.Clinical efficacy,liver function indices(aspartate aminotransferase,alanine aminotransferase,total bilirubin,and albumin),tumor serum markers,and adverse reactions were compared between the groups.RESULTS The objective response and disease control rates were significantly higher in group A(80.23%and 97.67%,respectively)than in group B(60.47%and 87.21%,respectively)(P<0.05).Post-treatment levels of aspartate aminotransferase,alanine aminotransferase,and total bilirubin were lower in group A than in group B(P<0.05),whereas post-treatment levels of albumin in group A were comparable to those in group B(P>0.05).Post-treatment levels of tumor serum markers were significantly lower in group A than in group B(P<0.05).Patients in groups A and B had mild-to-moderate fever and vomiting symptoms,which improved with conservative treatment.The total incidence of adverse reactions was significantly higher in group B(22.09%)than in group A(6.97%)(P<0.05).CONCLUSION DEB-TACE has obvious therapeutic effects on patients with PHC.It can improve liver function indices and tumor markers of patients without increasing the rate of liver toxicity or adverse reactions.
基金supported by the Tianjin“Belt and Road”Technological Innovation and Cooperation Grant(Grant No.18PTZWHZ00050)the Special Foundation for Project and Team Development Grant(Grant No.XB202008).
文摘Objective:The number of immediate breast reconstruction(IBR)procedures has been increasing in China.This study aimed to investigate the oncological safety of IBR,and to compare the survival and surgical outcomes between implant-based and autologous reconstruction.Methods:Data from patients diagnosed with invasive breast cancer who underwent immediate total breast reconstruction between 2001 and 2016 were retrospectively reviewed.Long-term breast cancer-specific survival(BCSS),disease-free survival(DFS),and locoregional recurrence-free survival(LRFS)were evaluated.Patient satisfaction with the breast was compared between the implantbased and autologous groups.BCSS,DFS,and LRFS were compared between groups after propensity score matching(PSM).Results:A total of 784 IBR procedures were identified,of which 584 were performed on patients with invasive breast cancer(implantbased,n=288;autologous,n=296).With a median follow-up of 71.3 months,the 10-year estimates of BCSS,DFS,and LRFS were 88.9%[95%confidence interval(CI)(85.1%–93.0%)],79.6%[95%CI(74.7%–84.8%)],and 94.0%[95%CI(90.3%–97.8%)],respectively.A total of 124 patients completed the Breast-Q questionnaire,and no statistically significant differences were noted between groups(P=0.823).After PSM with 27 variables,no statistically significant differences in BCSS,DFS,and LRFS were found between the implant-based(n=177)and autologous(n=177)groups.Further stratification according to staging,histological grade,lymph node status,and lymph-venous invasion status revealed no significant survival differences between groups.Conclusions:Both immediate implant-based and autologous reconstruction were reasonable choices with similar long-term oncological outcomes and patient-reported satisfaction among patients with invasive breast cancer in China.
